Want to join the conversation?
$AMGN Amgen today announced submission of NDA with United States Food& Drug Administration for etelcalcetide (formerly AMG 416) for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. If approved, etelcalcetide will be the first calcimimetic agent that can be administered IV at end of dialysis session
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.